Adalvo is very proud to announce the successful DCP approval for Pregabalin Prolonged Release Tablets.
Pregabalin Prolonged Release Tablets is a backbone medication indicated in the treatment of Neuropathic pain. Having a unique formulation allows for the product to yield an increase in patient adherence to the therapy through the reduction of the daily administration requirements.
Pregabalin Prolonged Release Tablets annual sales is $2bn, according to 2022 IQVIA.
Adalvo takes pride in this achievement and looks forward to providing Pregabalin Prolonged Release to patients globally.
Partner up now!
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - South Europe
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
bruno.alves@adalvo.com - Brazil
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!